PRIMED
Acute cerebral ischemia
Assessment tool
Neuroprotection
Translational readiness
Journal
Translational stroke research
ISSN: 1868-601X
Titre abrégé: Transl Stroke Res
Pays: United States
ID NLM: 101517297
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
27
02
2021
accepted:
26
05
2021
revised:
26
04
2021
pubmed:
2
7
2021
medline:
30
4
2022
entrez:
1
7
2021
Statut:
ppublish
Résumé
Many neuroprotective and other therapies for treatment of acute ischemic stroke have failed in translation to human studies, indicating a need for more rigorous, multidimensional quality assessment of the totality of preclinical evidence supporting a therapy prior to conducting human trials. A consensus panel of stroke preclinical model and human clinical trial experts assessed candidate items for the translational readiness scale, compiled from prior instruments (STAIR, ARRIVE, CAMARADES, RoB 2) based on importance, reliability, and feasibility. Once constructed, the tool was applied by two independent raters to four current candidate acute stroke therapies, including two pharmacologic agents [nerinetide and trans-sodium crocetinate] and two device interventions [cathodal transcranial direct current stimulation and fastigial nucleus stimulation]. The Preclinical evidence of Readiness In stroke Models Evaluating Drugs and Devices (PRIMED
Identifiants
pubmed: 34196953
doi: 10.1007/s12975-021-00922-4
pii: 10.1007/s12975-021-00922-4
pmc: PMC8918446
doi:
Substances chimiques
Neuroprotective Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
222-227Subventions
Organisme : NINDS NIH HHS
ID : R01 NS101362
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS095123
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS112996
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
J Neurosci Res. 2015 Apr;93(4):615-22
pubmed: 25491171
J Cereb Blood Flow Metab. 1993 Nov;13(6):1013-9
pubmed: 8408309
Stroke. 2009 Mar;40(3 Suppl):S111-4
pubmed: 19064810
Transl Stroke Res. 2013 Jun;4(3):279-85
pubmed: 23658596
Stroke. 2016 Jan;47(1):267-72
pubmed: 26658439
Stroke. 2013 Nov;44(11):3166-74
pubmed: 23982710
J Cereb Blood Flow Metab. 2016 Mar;36(3):555-61
pubmed: 26661213
N Engl J Med. 2015 Feb 5;372(6):528-36
pubmed: 25651247
J Cereb Blood Flow Metab. 2011 Mar;31(3):962-75
pubmed: 20978519
Brain Res. 1998 Jan 5;780(1):161-5
pubmed: 9497093
J Neurosurg. 2010 Oct;113(4):802-9
pubmed: 19961314
Br J Pharmacol. 2008 Mar;153 Suppl 1:S112-9
pubmed: 18311155
Front Psychol. 2019 Apr 11;10:813
pubmed: 31031679
Brain Res. 2014 Oct 2;1583:245-54
pubmed: 25128603
Nature. 2012 Feb 29;483(7388):213-7
pubmed: 22388811
Acta Pharmacol Sin. 2018 May;39(5):661-668
pubmed: 29565039
Lancet. 2020 Mar 14;395(10227):878-887
pubmed: 32087818
Stroke. 2008 Sep;39(9):2544-53
pubmed: 18617669
J Cereb Blood Flow Metab. 1991 Sep;11(5):810-8
pubmed: 1874812
Clin Neurol Neurosurg. 2015 Feb;129:1-9
pubmed: 25497127
J Neurosci. 1999 May 15;19(10):4142-54
pubmed: 10234042
Brain Res. 2001 Aug 31;912(1):47-59
pubmed: 11520492
Curr Neuropharmacol. 2020;18(7):596-612
pubmed: 31934841
Science. 2002 Oct 25;298(5594):846-50
pubmed: 12399596
Brain Res. 2010 Jan 14;1309:136-45
pubmed: 19891959
CNS Drugs. 2001;15(3):165-74
pubmed: 11463125
J Neurol Sci. 2014 Jul 15;342(1-2):146-51
pubmed: 24857352
Ann Neurol. 2020 Jan;87(1):40-51
pubmed: 31714631
J Cereb Blood Flow Metab. 1993 Nov;13(6):1020-4
pubmed: 8408310